What question did this study set out to answer?

This research aims to evaluate the safety and pharmacokinetics of a chemotherapy-free treatment for relapsed primary CNS lymphoma.

February 2, 2026CancersOpen Access

The Phase Ib VenObi CNS Study: Chemotherapy-Free Treatment with Venetoclax and Obinutuzumab for Relapsed/Refractory Primary Large B-Cell Lymphoma of the Central Nervous System

View Full Paper

Ask AI

Bookmark

Authors

Phase Ib study investigates chemotherapy-free treatment effects in relapsed primary CNS lymphoma, suggesting potential benefits.

This research aims to evaluate the safety and pharmacokinetics of a chemotherapy-free treatment for relapsed primary CNS lymphoma.
Conducted a bi-centric phase Ib dose-escalation study in Germany.
Administered venetoclax with obinutuzumab to patients with relapsed/refractory PCNSL.
Included 6 cycles of fixed-dose obinutuzumab every 3 weeks and a venetoclax maintenance period of 12 months.
Monitored pharmacokinetics of venetoclax and obinutuzumab in cerebrospinal fluid.
Study was prematurely terminated with 33% patient registration in the first dosing group.
Mean CSF concentration of venetoclax was 0.55% and for obinutuzumab was 0.25% compared to peripheral blood.
Two patients achieved complete remission; one had partial remission and one stable disease.
Median duration of response was 6.5 months.

Wendler et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark